Short answer
STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Microfluidics business sale to ARCHIMED closed on November 3, 2026.
STANDARD BIOTOOLS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Microfluidics business sale to ARCHIMED closed on November 3, 2026
- Transaction completes Standard BioTools’ previously announced divestiture and transfers future business ownership to ARCHIMED
- ARCHIMED assumes responsibility for integrating, developing, and commercializing Microfluidics technology and products
- Sale announcement may signal portfolio streamlining as Standard BioTools pursues pending Treeline and Element transactions
Item EX-99.1 · Exhibit EX-99.1
- ARCHIMED completed the acquisition of Standard BioTools’ Microfluidics Business, separating it from LAB’s operating portfolio
- Business relaunched as Biomark Scientific, retaining the Biomark platform, Biomark X9 system and existing team
- Biomark Scientific now operates as an independent ARCHIMED-backed company focused on genomic workflows, clinical research and public health
- For LAB shareholders, transaction marks a portfolio shift toward Standard BioTools’ remaining life-science tools businesses and away from microfluidics നേതൃത്വം
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STANDARD BIOTOOLS INC. 8-K filings
Get the next LAB 8-K as it lands
Follow LAB for push alerts, or ask the research agent what this filing means.